Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Kufe
Massachusetts Institute of Technology, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genus Oncology
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Genus Oncology is private clinical-stage biopharmaceutical company focused on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers. This R01 grant proposes to utilize a novel synthetic strategy to make safe nanoparticle (NP)-drug conjugates and enable magnetic resonance imaging (MRI)- guided therapeutic selection. The project’s objectives are to construct NPs from combinations of drugs that are synergistic for ovarian cancer, and to determine if the therapy is working by using responsive organic MRI tags built into the NPs. NP delivery to solid tumor malignancies will be augmented using a novel humanized antibody that binds MUC1-C, MAb 3D1. This antibody is licensed to Genus Oncology.
The DFCI Conflict of Interest Committee concluded that the results of this research could be of scientific and financial interest to genus Oncology and, accordingly, represented a financial conflict of interest under the regulations.
Organic nanoparticles for dual MRI-guided therapeutic selection and ovarian cancer drug delivery
This proposal describes a new way to make safe nanoparticles that can carry multiple drugs and enable MRI- guided therapeutic selection. Our key objectives are to construct these nanoparticles from combinations of drugs that are synergistic for ovarian cancer, and to determine if the therapy is working by using responsive organic MRI imaging tags built into the nanoparticles. Our hypothesis is that these new nanoparticles will provide a clinically translatable theranostics platform for ovarian cancer imaging and therapy.
Filed on December 27, 2017.
Tell us what you know about Donald Kufe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Donald Kufe”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Massachusetts Institute of Technology | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $0 - $4,999 |
| Donald Kufe | Massachusetts Institute of Technology | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.